These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16320012)

  • 1. [Health economic evaluation of disease management programs].
    Greiner W
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Jan; 49(1):34-9. PubMed ID: 16320012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Health economics as the basis for the synthesis of efficiency and financial soundness in statutory health insurance].
    Straub C
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Jan; 49(1):73-80. PubMed ID: 16333646
    [No Abstract]   [Full Text] [Related]  

  • 3. [Aspects of economic evaluation in health care].
    Noelle G; Jaskulla E; Sawicki PT
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Jan; 49(1):28-33. PubMed ID: 16341607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Health economics. Objectives, methodology, relevance].
    Busse R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Jan; 49(1):3-10. PubMed ID: 16333644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Health economics of psychological diseases].
    König HH; Friemel S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Jan; 49(1):46-56. PubMed ID: 16362133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Health economic research in rheumatic diseases].
    Mittendorf T; Graf von der Schulenburg JM
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Jan; 49(1):40-5. PubMed ID: 16333645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cost of illness studies as a basis for decision making].
    Henke KD; Martin K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Jan; 49(1):19-27. PubMed ID: 16341605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Health economics of chronic infectious diseases: the example of hepatitis C].
    Wasem J; Sroczynski G; Aidelsburger P; Buchberger B; Hessel F; Conrads-Frank A; Peters-Blöchinger A; Kurth BM; Wong JB; Rossol S; Siebert U
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Jan; 49(1):57-63. PubMed ID: 16341606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Decision support through economic evaluation from the perspective of science in Germany].
    Graf von der Schulenburg JM
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 May; 55(5):660-7. PubMed ID: 22526854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Decision-analytical modelling of costs per QALY in the context of the German Social Law].
    Rogowski WH; Landauer M; John J
    Gesundheitswesen; 2009 Nov; 71(11):739-50. PubMed ID: 19551622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Disease management programs: Difficulties in the analysis of benefit].
    Linder R; Horenkamp-Sonntag D; Bestmann B; Battmer U; Heilmann T; Verheyen F
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Apr; 58(4-5):345-51. PubMed ID: 25708909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Health economic aspects of the use of blood and blood products].
    Berger K; Frey L; Spannagl M; Schramm W
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Jan; 49(1):64-72. PubMed ID: 16362134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Usability of databases in health economics].
    Brüggenjürgen B; Willich SN
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Jan; 49(1):11-8. PubMed ID: 16362135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Options for a future risc structure compensation in Germany].
    Greiner W
    Gesundheitswesen; 2006 Jul; 68(7):442-8. PubMed ID: 16868871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Health economic evaluation based on administrative data from German health insurance].
    Schreyögg J; Stargardt T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 May; 55(5):668-74. PubMed ID: 22526855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broader economic evaluation of disease management programs using multi-criteria decision analysis.
    Tsiachristas A; Cramm JM; Nieboer A; Rutten-van Mölken M
    Int J Technol Assess Health Care; 2013 Jul; 29(3):301-8. PubMed ID: 23759317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 'Health Economics' and the evolution of economic evaluation of health technologies.
    Hutton J
    Health Econ; 2012 Jan; 21(1):13-8. PubMed ID: 22147623
    [No Abstract]   [Full Text] [Related]  

  • 18. [Rationing in German health care with particular consideration of oncology: view points of German stakeholders--a qualitative interview study].
    Lange J; Gönner C; Vollmann J; Rauprich O
    Gesundheitswesen; 2015 Jan; 77(1):8-15. PubMed ID: 24696371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A changing medical and economic world: complex diseases and interest in economic evaluation of health technologies].
    Hiligsmann M; Reginster JY
    Rev Med Liege; 2012; 67(5-6):258-62. PubMed ID: 22891476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population.
    Tscheulin DK; Drevs F
    Eur J Health Econ; 2010 Apr; 11(2):141-50. PubMed ID: 19449159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.